JP2009540278A - 前立腺癌腫の検出のためのモノクローナル抗アネキシンａ３抗体 - Google Patents
前立腺癌腫の検出のためのモノクローナル抗アネキシンａ３抗体 Download PDFInfo
- Publication number
- JP2009540278A JP2009540278A JP2009513608A JP2009513608A JP2009540278A JP 2009540278 A JP2009540278 A JP 2009540278A JP 2009513608 A JP2009513608 A JP 2009513608A JP 2009513608 A JP2009513608 A JP 2009513608A JP 2009540278 A JP2009540278 A JP 2009540278A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- annexin
- seq
- tgc
- dsm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 31
- 201000001514 prostate carcinoma Diseases 0.000 title abstract description 14
- 238000001514 detection method Methods 0.000 title description 7
- 108090000670 Annexin A3 Proteins 0.000 claims abstract description 92
- 102000004120 Annexin A3 Human genes 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 50
- 238000003745 diagnosis Methods 0.000 claims abstract description 10
- 238000012360 testing method Methods 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 30
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 25
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 25
- 210000002700 urine Anatomy 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 22
- 101000924454 Homo sapiens Annexin A3 Proteins 0.000 claims description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 19
- 102000000412 Annexin Human genes 0.000 claims description 18
- 108050008874 Annexin Proteins 0.000 claims description 18
- 230000009260 cross reactivity Effects 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 210000004408 hybridoma Anatomy 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 230000001744 histochemical effect Effects 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 230000002550 fecal effect Effects 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000024558 digestive system cancer Diseases 0.000 claims 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 2
- 208000037964 urogenital cancer Diseases 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 1
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 239000000523 sample Substances 0.000 description 24
- 239000012634 fragment Substances 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 15
- 210000000416 exudates and transudate Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 9
- 102000053517 human ANXA3 Human genes 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 238000007388 punch biopsy Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000000464 low-speed centrifugation Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102100034278 Annexin A6 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 102100034618 Annexin A3 Human genes 0.000 description 1
- 102100034283 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 108050002216 Annexin A8 Proteins 0.000 description 1
- 102100036824 Annexin A8 Human genes 0.000 description 1
- 101100344898 Arabidopsis thaliana MED13 gene Proteins 0.000 description 1
- 101100350216 Arabidopsis thaliana PDH2 gene Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000780137 Homo sapiens Annexin A6 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 208000029499 cancer-related condition Diseases 0.000 description 1
- -1 carboxy, amino Chemical group 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002284 membrane microdomain Anatomy 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4718—Lipocortins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81208906P | 2006-06-09 | 2006-06-09 | |
| US85948906P | 2006-11-17 | 2006-11-17 | |
| PCT/EP2007/005134 WO2007141043A2 (en) | 2006-06-09 | 2007-06-11 | Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009540278A true JP2009540278A (ja) | 2009-11-19 |
| JP2009540278A5 JP2009540278A5 (enExample) | 2010-07-29 |
Family
ID=38653814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513608A Ceased JP2009540278A (ja) | 2006-06-09 | 2007-06-11 | 前立腺癌腫の検出のためのモノクローナル抗アネキシンａ３抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8012697B2 (enExample) |
| EP (1) | EP2024748B1 (enExample) |
| JP (1) | JP2009540278A (enExample) |
| KR (1) | KR20090023372A (enExample) |
| AU (1) | AU2007256377B2 (enExample) |
| CA (1) | CA2654330A1 (enExample) |
| DE (1) | DE07725949T1 (enExample) |
| DK (1) | DK2024748T3 (enExample) |
| ES (1) | ES2396730T3 (enExample) |
| PL (1) | PL2024748T3 (enExample) |
| PT (1) | PT2024748E (enExample) |
| RU (1) | RU2467335C2 (enExample) |
| WO (1) | WO2007141043A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1724586A3 (en) * | 2005-05-21 | 2007-07-04 | ProteoSys AG | Annexin for cancer risk assessment |
| JP2012503634A (ja) * | 2008-09-26 | 2012-02-09 | プロテオシス アクチエンゲゼルシャフト | 天然のアネキシンａ３を認識する新規抗体 |
| FR2968767B1 (fr) | 2010-12-08 | 2012-12-21 | Biomerieux Sa | Procede et coffret pour le diagnostic in vitro du cancer de la prostate |
| WO2013076222A1 (en) | 2011-11-23 | 2013-05-30 | Proteosys Ag | Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer |
| FR2991777B1 (fr) * | 2012-06-07 | 2015-08-21 | Biomerieux Sa | Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives |
| US9487831B2 (en) * | 2013-09-12 | 2016-11-08 | Versitech Limited | Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma |
| US9470677B2 (en) | 2013-11-28 | 2016-10-18 | Samsung Electronics Co., Ltd. | Cell with surface coated with ANXA1 and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005078124A2 (de) * | 2004-02-16 | 2005-08-25 | Proteosys Ag | Diagnostische marker für krebs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4104910C3 (de) | 1991-02-18 | 2000-02-24 | Schloemann Siemag Ag | Stahlnachbehandlungsanlage |
| US5136855A (en) | 1991-03-05 | 1992-08-11 | Ontario Hydro | Heat pump having an accumulator with refrigerant level sensor |
| US20030108963A1 (en) * | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
| DE10217254A1 (de) | 2002-04-15 | 2003-10-23 | Proteosys Ag | Verwendung von Substanzen zur Behandlung von Tumoren |
| EP1724585A1 (en) * | 2005-05-21 | 2006-11-22 | ProteoSys AG | Annexin for cancer risk assessment |
| EP1724586A3 (en) | 2005-05-21 | 2007-07-04 | ProteoSys AG | Annexin for cancer risk assessment |
-
2007
- 2007-06-11 DK DK07725949.7T patent/DK2024748T3/da active
- 2007-06-11 JP JP2009513608A patent/JP2009540278A/ja not_active Ceased
- 2007-06-11 PL PL07725949T patent/PL2024748T3/pl unknown
- 2007-06-11 EP EP07725949A patent/EP2024748B1/en active Active
- 2007-06-11 ES ES07725949T patent/ES2396730T3/es active Active
- 2007-06-11 RU RU2008152009/15A patent/RU2467335C2/ru not_active IP Right Cessation
- 2007-06-11 DE DE07725949T patent/DE07725949T1/de active Pending
- 2007-06-11 US US12/303,825 patent/US8012697B2/en not_active Expired - Fee Related
- 2007-06-11 KR KR1020087029969A patent/KR20090023372A/ko not_active Ceased
- 2007-06-11 PT PT77259497T patent/PT2024748E/pt unknown
- 2007-06-11 CA CA002654330A patent/CA2654330A1/en not_active Abandoned
- 2007-06-11 WO PCT/EP2007/005134 patent/WO2007141043A2/en not_active Ceased
- 2007-06-11 AU AU2007256377A patent/AU2007256377B2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005078124A2 (de) * | 2004-02-16 | 2005-08-25 | Proteosys Ag | Diagnostische marker für krebs |
| JP2007527001A (ja) * | 2004-02-16 | 2007-09-20 | プロテオジス アクチェンゲゼルシャフト | がんに関する診断マーカー |
Non-Patent Citations (1)
| Title |
|---|
| JPN5009007979; ＬＥ ＣＡＢＥＣ Ｖ: ＢＩＯＣＨＥＭ ＢＩＯＰＨＹＳ ＲＥＳ ＣＯＭＭＵＮ Ｖ１８９ Ｎ３, 19921230, Ｐ１４７１-１４７６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE07725949T1 (de) | 2009-07-02 |
| WO2007141043A3 (en) | 2008-03-20 |
| EP2024748B1 (en) | 2012-12-12 |
| WO2007141043A2 (en) | 2007-12-13 |
| RU2467335C2 (ru) | 2012-11-20 |
| US8012697B2 (en) | 2011-09-06 |
| AU2007256377A1 (en) | 2007-12-13 |
| US20100233160A1 (en) | 2010-09-16 |
| ES2396730T3 (es) | 2013-02-25 |
| EP2024748A2 (en) | 2009-02-18 |
| CA2654330A1 (en) | 2007-12-13 |
| AU2007256377B2 (en) | 2012-11-01 |
| PL2024748T3 (pl) | 2013-05-31 |
| KR20090023372A (ko) | 2009-03-04 |
| PT2024748E (pt) | 2013-01-16 |
| DK2024748T3 (da) | 2013-03-18 |
| RU2008152009A (ru) | 2010-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cozzi et al. | MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer | |
| CN101473041B (zh) | He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用 | |
| CN106661110B (zh) | 抗muc1抗体或其抗原结合片段及其用途 | |
| RU2467335C2 (ru) | Моноклональные антитела против аннексина а3 для обнаружения карциномы простаты | |
| US20050221397A1 (en) | RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as prostate cancer-associated antigen | |
| WO2012031374A1 (zh) | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 | |
| JP2012524521A (ja) | グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法 | |
| CN108700586A (zh) | 用于评估癌症发生的风险的组合物和方法 | |
| CN102803968B (zh) | 食道癌标志物 | |
| KR101777259B1 (ko) | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
| WO2006031986A2 (en) | Methods and compositions for diagnosing neoplastic disease | |
| KR20120095301A (ko) | 항-사이토케라틴 8/18 복합체 자가면역항체를 포함하는 암 진단 마커 및 이의 항원을 포함하는 암 진단용 조성물 | |
| KR101777254B1 (ko) | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
| US20110177536A1 (en) | Novel antibodies recognizing native annexin a3 | |
| JP2010522884A (ja) | 乳がんの評価のためのｈｅ４の使用 | |
| JP2022521535A (ja) | 前立腺がんのバイオマーカとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用 | |
| JP2023145633A (ja) | 乳がんのバイオマーカとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用 | |
| KR102280473B1 (ko) | 악성 신생물 질환의 검출을 위한 조성물 및 방법 | |
| CN110036119B (zh) | 卵巢癌生物标记及其应用 | |
| KR101777085B1 (ko) | En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물 | |
| CN101501501A (zh) | 用于检测前列腺癌的抗膜联蛋白a3单克隆抗体 | |
| JPWO2006118338A1 (ja) | 腫瘍の診断剤 | |
| US20050272102A1 (en) | Method for diagnosis of prostate cancer | |
| CN106191022A (zh) | 一种肿瘤特异抗原及其应用 | |
| HK1160869A (en) | Novel antibodies recognizing native annexin a3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100527 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100527 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101227 Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110930 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120130 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120206 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20120206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120229 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120314 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120822 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121120 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121225 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130116 |
|
| RD14 | Notification of resignation of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7434 Effective date: 20130225 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130708 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20131125 |